Announcements

The deadline is approaching for investigators to submit subprotocol concept sheets for the new ComboMATCH trial. The deadline is Friday, June 28th More Here

Don’t miss the May 2019 newsletter

Latest News

TAILORx

• New TAILORx data guides adjuvant therapy in younger breast cancer patients Press Release
  
  
• The New England Journal of Medicine publishes analysis of a pre-specified secondary analysis that adds new information to the original TAILORx findings NEJM Article
  
  
• “The Precision of Evidence Needed to Practice “Precision Medicine” NEJM Accompanying Editorial
  
  
• Updated ASCO guidelines establish TAILORx-defined cutoffs for determining chemotherapy benefit with the Oncotype DX Breast Recurrence Score^® test in node-negative breast cancer Press Release
  
  
• One Year Post-TAILORx: Attitudes Shift and Questions Linger in Breast Cancer Recurrence Testing GenomeWeb (requires free registration) 
  
  
• Using Genomic Profiling to Guide Treatment Decisions for ER-Positive Breast Cancers, by Harold J. Burstein, MD, PhD CancerNetwork
  
  
• New TAILORx Data Provide Treatment Guidance for Women Under 50 With Early Breast Cancer The ASCO Post

NCI-MATCH

• Arm H finds the combination of dabrafenib and trametinib effective in a heavily pre-treated cohort of 17 distinct tumor types–several rare–with BRAF mutations Press Release
  
  
• Keith Flaherty, MD, ECOG-ACRIN study chair, comments on targeted drugs in an article on basket trials published in Xconomy National

E2810

• Final results show no benefit from pazopanib in advanced kidney cancer after surgery to remove metastases Press Release
  
  
• ASCO 2019: Randomized, Double-Blind Phase III Study of Pazopanib versus Placebo in Patients with Metastatic Renal Cell Carcinoma who have no Evidence of Disease Following Metastasectomy – Medical Oncologist Perspective UroToday
  

• No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases Medical Xpress

E3A06

• Final results demonstrate that lenalidomide reduces the risk that precancer myeloma will progress to overt multiple myeloma in high-risk individuals Press Release

TMIST

• “Why I choose to play a dual role in TMIST” by Worta McCaskill-Stevens, Division of Cancer Prevention, National Cancer Institute, in The Cancer Letter More Here
  
  
• “Are we further reducing breast cancer mortality the more intensively we screen?” Conversation with The Cancer Letter and TMIST study chair Etta Pisano, MD More Here

Group Meeting Highlights

Welcome

Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.

The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.

We look forward to sharing our research and partnering with you, as we reshape the future of patient care.

 

Robert L. Comis, MD
Group Co-Chair

Mitchell D. Schnall, MD, PhD
Group Co-Chair